We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
-17.71%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$504M
AUM Growth
-$396M
Cap. Flow
-$283M
Cap. Flow %
-56.16%
Top 10 Hldgs %
63.87%
Holding
48
New
7
Increased
17
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$40M
2
ELV icon
Elevance Health
ELV
+$27.4M
3
SHPG
Shire pic
SHPG
+$20.2M
4
LH icon
Labcorp
LH
+$14.2M
5
LCI
Lannett Company, Inc.
LCI
+$7.19M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$132M
2
VTRS icon
Viatris
VTRS
+$42.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$42.4M
4
AET
Aetna Inc
AET
+$35.9M
5
STJ
St Jude Medical
STJ
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88%
2 Financials 4.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
1
DELISTED
NEVRO CORP.
NVRO
$83.5M 16.57%
1,483,730
-199,147
-12% -$11.7M
AMGN icon
2
Amgen
AMGN
$197B
$40.4M 8.02%
+269,300
New +$40M
AGN
3
DELISTED
Allergan plc
AGN
$38.5M 7.65%
143,748
+19,248
+15% +$5.51M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$36.1B
$29.9M 5.94%
558,889
-722,300
-56% -$42.4M
ELV icon
5
Elevance Health
ELV
$82.9B
$28.5M 5.65%
+204,700
New +$27.4M
AET
6
DELISTED
Aetna Inc
AET
$22.5M 4.46%
200,000
-335,532
-63% -$35.9M
TVTY
7
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$22.4M 4.45%
2,221,481
-303,563
-12% -$3.41M
SHPG
8
DELISTED
Shire pic
SHPG
$20.7M 4.12%
+120,700
New +$20.2M
CNCE
9
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$20.1M 3.99%
1,471,693
+39,076
+3% +$562K
TVTX icon
10
Travere Therapeutics
TVTX
$5.16B
$15.2M 3.02%
1,114,592
+55,710
+5% +$845K
LH icon
11
Labcorp
LH
$23.1B
$14.9M 2.95%
+147,595
New +$14.2M
INSM icon
12
Insmed
INSM
$23.2B
$14M 2.78%
1,104,998
+415,891
+60% +$5.47M
ALDR
13
DELISTED
Alder Biopharmaceuticals
ALDR
$12.6M 2.5%
513,570
-43,600
-8% -$1.01M
UHS icon
14
Universal Health Services
UHS
$9.12B
$11.2M 2.22%
89,500
-45,700
-34% -$5.14M
MNTA
15
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$11.1M 2.2%
1,199,891
+657,800
+121% +$7.08M
ITCI
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.6M 2.11%
382,924
+30,000
+9% +$1,000K
FOMX
17
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$10.4M 2.07%
1,599,031
+101,600
+7% +$655K
ENTA icon
18
Enanta Pharmaceuticals
ENTA
$383M
$9.95M 1.98%
338,851
+174,865
+107% +$4.87M
ELOS
19
DELISTED
Syneron Medical Ltd
ELOS
$9.27M 1.84%
1,267,982
-138,300
-10% -$991K
TNDM icon
20
Tandem Diabetes Care
TNDM
$1.24B
$7.75M 1.54%
88,945
-4,060
-4% -$355K
SEM
21
DELISTED
Select Medical
SEM
$7.64M 1.52%
1,200,134
+286,982
+31% +$1.54M
ANIP icon
22
ANI Pharmaceuticals
ANIP
$1.77B
$7.54M 1.5%
223,871
-229,981
-51% -$7.8M
CORI
23
DELISTED
Corium International, Inc.
CORI
$6.7M 1.33%
1,735,966
+414,487
+31% +$2.18M
RCKT icon
24
Rocket Pharmaceuticals
RCKT
$375M
$5.53M 1.1%
186,975
+109,575
+142% +$3.29M
DERM
25
DELISTED
Dermira, Inc.
DERM
$5.45M 1.08%
263,300
+15,800
+6% +$388K
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Senzar Asset Management held 48 positions worth $504M, down 44% from $899M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Senzar Asset Management withdrew a net $283M in Q1 2016, closing 11 positions and reducing 13 holdings. Its most notable exit was Bausch Health, an estimated $132M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier, followed by Financials.

Against the trend, Senzar Asset Management opened a new position in Amgen worth $40.4M.

  • Senzar Asset Management's largest Q1 2016 buy was Amgen: 269,300 shares worth $40.4M.
  • Senzar Asset Management added most to Momenta Pharmaceuticals, Inc. in Q1 2016, an estimated $7.08M increase.
  • Senzar Asset Management's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $42.4M.
  • Senzar Asset Management fully exited Bausch Health in Q1 2016, selling an estimated $132M.
  • Senzar Asset Management's ten largest holdings make up 64% of its $504M portfolio in Q1 2016.
  • Senzar Asset Management opened 7 new positions and closed 11 in Q1 2016.
  • Senzar Asset Management's portfolio value fell 44% quarter-over-quarter to $504M.

Based on Senzar Asset Management's 13F filing for Q1 2016, filed 13 May 2016.